

Appendix 3 (as supplied by the authors): Results of sensitivity analyses for insulin analogues in the treatment of adults with diabetes in Canada, by type of diabetes and treatment comparison

Comparison	Fear of hypoglycemia			Difference in glycosylated hemoglobin% = 0		
	Cost (Can\$)	Difference		Cost (Can\$)	Difference	
		Quality adjusted life years gained	Cost per quality adjusted life years gained		Quality adjusted life years gained	Cost per quality adjusted life years gained
Type 1 diabetes						
Insulin aspart v. regular human insulin	-621	0.212	cost-saving	174	0.002	104 598
Insulin lispro v. regular human insulin	182	0.163	1 117	271	0.0004	673 041
Insulin glargine v. insulin neutral protamine hagedorn	3 423	0.199	17 225	3 689	0.004	916 401
Insulin detemir v. insulin neutral protamine hagedorn	4 344	0.169	25 666	4 288	0.002	1 958 928
Type 2 diabetes						
Insulin aspart v. regular human insulin	333	0.075	4 429	749	0.001	543 584
Insulin lispro v. regular human insulin	784	0.065	12 115	1 092	0.014	80 445†
Insulin glargine v. insulin neutral protamine hagedorn	4 945	0.067	73 989	5 199	0.003	1 577 457
Insulin detemir v. insulin neutral protamine hagedorn	6 521	0.028	234 606	6 287	0.007	882 155

Note: †Counterintuitive incremental cost per quality adjusted life-year gained may be attributable to random variation of model iterations and small glycosylated hemoglobin% differences.